Idelalisib given front-line for treatment of c... - CLL Support

CLL Support

23,324 members40,026 posts

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Cllcanada profile image
CllcanadaTop Poster CURE Hero
2 Replies

Key Points

Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease.

Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.

Full PDF

bloodjournal.org/content/bl...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
2 Replies
wroxham-gb profile image
wroxham-gb

Photo so clear. Great.

Not so sure about Idealisib.

Sue

mnmnewtons profile image
mnmnewtons

Excellent! I am on Zydelig and need to know what to look for

Thanks

Not what you're looking for?

You may also like...

Chronic lymphocytic leukemia treatment algorithm 2022

This 29 November 2022 review article published in the Blood Cancer Journal presents an...
CLLerinOz profile image
Administrator

BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

It gets kinda technical but this is some great research on ibrutinib resistance by Dr. Woyach....
bkoffman profile image
CLL CURE Hero

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Good News for our untreated Canadian members! This latest approval is based on...
AussieNeil profile image
Partner

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Jan 19,...
lankisterguy profile image
Volunteer

Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This is a short paper setting out the non trial option for patients needing treatment after a...
Jm954 profile image
Administrator